Fig. 5
EDARADD methylation and expression are associated with poor relapse-free survival in prostate cancer cohorts. a, b Kaplan Meier plots of relapse free survival for patients in the lowest quartile of EDARADD methylation (bottom 0.25, orange) versus the rest of each cohort (top 0.75, grey). c Forest plot showing the Cox hazard ratios (± 95% CI) for relapse free survival based on EDARADD methylation and a meta-analysis of both methylation datasets (Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 = 0%; Test for overall effect: Z = 3.14 (P = 0.002)). d–h Kaplan Meier plots of relapse free survival for patients in the highest quartile of EDARADD expression (top 0.25, orange) versus the rest of each cohort (bottom 0.75, grey) for the TCGA and Fraser datasets. i Forest plot showing the Cox hazard ratios (± 95% CI) for relapse-free survival based on EDARADD expression and a meta-analysis of all methylation datasets (Heterogeneity: Chi2 = 5.45, df = 4 (P = 0.24); I2 = 27%; Test for overall effect: Z = 5.74 (P < 0.00001))